Written By: BrightFocus Editorial Staff
The following statement was issued today by Stacy Pagos Haller, BrightFocus Foundation President and CEO:
The Alzheimer’s advocacy movement has lost a great friend in Trish Vradenburg.
Funny, fearless, passionate, and persistent, Trish inspired us and led by an example we all strove to emulate. Her infectious humor and selfless activism made us better people and better advocates. Our shared mission to end Alzheimer’s became stronger, bolder, and certainly livelier and funnier because of Trish.
On behalf of BrightFocus Foundation, I want to express our deepest sympathies and support for the Vradenburg family, USAgainstAlzheimer’s, and all whose lives she touched and changed. In this time of great sadness, it will be in Trish’s name and Trish’s honor that we redouble our efforts to defeat this disease.
BrightFocus Foundation is a premier global nonprofit funder of research to defeat Alzheimer’s, macular degeneration, and glaucoma. Through its flagship research programs — Alzheimer’s Disease Research, Macular Degeneration Research, and National Glaucoma Research— the Foundation has awarded nearly $300 million in groundbreaking research funding over the past 51 years and shares the latest research findings, expert information, and resources to empower the millions impacted by these devastating diseases. Learn more at brightfocus.org.
Disclaimer: The information provided here is a public service of BrightFocus Foundation and is not intended to constitute medical advice. Please consult your physician for personalized medical, dietary, and/or exercise advice. Any medications or supplements should only be taken under medical supervision. BrightFocus Foundation does not endorse any medical products or therapies.
BrightFocus Foundation received a $3.2 million grant from an anonymous foundation to support 12 new Alzheimer’s Disease Research grants.
Report shows that boosting research investment into the wellbeing of adults with Down syndrome would improve their quality-of-life outcomes, reduce caregiving costs, and extend the lifespan of adults with Down syndrome by five years.
Another disease-modifying Alzheimer's therapy hits the market.
An FDA decision on Eli Lilly's donanemab is expected in the coming months.
